Skip to main content

Advertisement

Table 5 Overall survival and time-to-progression (n = 66)

From: Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Characteristic OS* (months) 95% CI 1-year survival rate (%) P-value TTP (months) 95% CI 1-year survival rate (%) P-value
Age <60
≥ 60
26.0
25.0
18.9-33.1
14.2-35.8
69.2
69.9
.656 6.0
6.0
2.8-9.2
0.8-11.2
26.9
35.4
.611
Sex Male
Female
22.0
27.0
15.9-28.1
19.3-34.7
69.1
69.6
.134 6.0
6.0
0.0-14.2
2.7-9.3
28.0
34.6
.771
  Pancreas 28.0 18.0-38.0 77.1 .981 7.0 0.0-15.0 41.6  
Origin GI 22.0 0.0-46.9 63.2   2.0 0.8-3.2 25.0 .258
  Lung 9.0 - 50.0   1.0 - -  
Liver metastasis Absent
Present
25.0
22.0
20.8-29.2
13.3-30.7
77.0
65.0
.310 12.0
4.0
9.2-14.8
1.3-6.7
40.7
23.8
.011
  1 36.0 13.2-58.8 72.4   12.0 8.3-15.7 57.5  
  2-3 17.0 1.1-32.9 53.0 .612 4.0 1.2-6.8 34.3  
Grade   .681
  Large 12.0 0.0-29.8 50.0   2.0 0.0-4.5 45.0  
  Small 17.0 10.1-23.9 100.0   12.0 2.6-21.4 30.0  
  24-hour urine 5-HIAA (μmol/day) <31.4 20.0 0.0-52.2 60.0 .114 1.0 - - .045
   ≥ 31.4 40.0 - 62.5   12.0 0.0-29.6 44.4  
Biomarkers  
  Serum NSE (nmol/l) <1.0
≥ 1.0
25.0
6.0
18.0-32.0
0.0-18.0
75.0
46.4
.170 2.0
4.0
0.9-3.1
1.2-6.8
0.0
22.2
.381
  IFN 36.0 22.6-49.4 86.7 .169 10.0 0.0-25.6 22.9  
Regimen Somatostatin-analogue 3.0 . 50.0   0.0 - - .057
  Chemotherapy 20.0 13.3-26.7 64.5   6.0 3.6-8.4 34.2  
Treatment modality Systemic treatment only
Systemic+local treatment
23.0
29.0
0.4-45.6
23.6-34.4
57.9
86.1
.350     
  1. OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon
  2. *OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.
  3. Somatostatin-analogue was given to only 2 patients.